A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors

Inclusion Criteria:

- Written informed consent

- Patients with confirmed advanced solid tumors.

- No prior chemotherapy within 5 years of the diagnosis of SCLC (small cell lung
cancer).

- At least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery.

- Laboratory criteria: Patients must have adequate bone marrow reserve and adequate
kidney and liver function.

Exclusion criteria:

- Women who are pregnant or lactating.

- Patients of child bearing potential refusing to practice adequate contraception.

- Patients with uncontrolled vomiting.

- Active infection.

- Patients with clinical evidence of any gastrointestinal (GI) conditions which would
alter GI absorption or GI motility.

- Patients requiring treatment with cyclosporin A.

- Severe medical problems other than the cancer, that would limit the ability of the
patient to follow study guidelines or expose the patient to extreme risk.

- Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational
therapy for cancer treatment.

- Use of investigational drug within 30 days prior to the first dose of study
medication.